Earnings ·
Pulmonx Corporation reported financial results for the second quarter ended June 30, 2026
LUNGPulmonx Corp
Pulmonx Corporation reported financial results for the second quarter ended June 30, 2026. Worldwide revenue decreased 5% to $22.8 million, driven by a lack of sales in China while international revenue excluding China grew 12%. The company achieved a record gross margin of 78%, and operating expenses fell 16% to $26.8 million due to cost realignment efforts. Net loss narrowed to $10.1 million ($0.24 per share) from $15.2 million in the prior year period, with adjusted EBITDA loss reducing by 39%. Cash and cash equivalents stood at $55.8 million as of June 30, 2026. The company maintained its full-year 2026 revenue guidance between $90 million and $92 million. Pulmonx Corporation operates in the medical device industry, developing minimally invasive treatments for chronic obstructive pulmonary disease (COPD).